Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

Molecular Cancer

Volumn 6, Issue , 2007, Pages

  Kaur, Pavinder ^a   Feldhahn, Niklas ^a   Zhang, Bin ^a,b   Trageser, Daniel ^a   Müschen, Markus ^a   Pertz, Veerle ^a   Groffen, John ^a   Heisterkamp, Nora ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB; PROTEIN P190; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; JANUS KINASE 2; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; EMBRYO; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; LYMPHATIC LEUKEMIA; LYMPHOMA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; SURVIVAL TIME; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL LEUKEMIA; FLOW CYTOMETRY; METABOLISM; STROMA CELL; TUMOR CELL LINE; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; JANUS KINASE 2; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; STROMAL CELLS;

EID: 37749053902     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-6-67     Document Type: Article

References (52)

1. Faderl S Jeha S Kantarjian HM The biology and therapy of adult acute lymphoblastic leukemia Cancer 2003, 98:1337-1354 10.1002/cncr.11664 14508819
2. Kurzrock R Kantarjian HM Druker BJ Talpaz M Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics Ann Intern Med 2003, 138:819-830 12755554
3. Laurent E Talpaz M Kantarjian H Kurzrock R The BCR gene and Philadelphia chromosome-positive leukemogenesis Cancer Res 2001, 61:2343-2355 11289094
4. Daley GQ Van Etten RA Baltimore D Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 1990, 247:824-830 10.1126/science.2406902 2406902
5. Lugo TG Pendergast AM Muller AJ Witte ON Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 1990, 247:1079-1082 10.1126/science.2408149 2408149
6. Ren R Mechanism of BCR-ABL in the pathogenesis of chronic myeloid leukaemia Nat Rev Cancer 2005, 5:172-183 10.1038/nrc1567 15719031
7. Druker BJ Talpaz M Resta DJ Peng B Buchdunger E Ford JM Lydon NB Kantarjian H Capdeville R Ohno-Jones S Sawyers CL Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001, 344:1031-1037 10.1056/NEJM200104053441401 11287972
8. Deininger M Buchdunger E Druker BJ The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 2005, 105:2640-2653 10.1182/blood-2004-08-3097 15618470
9. Druker BJ O'Brien SG Cortes J Radich J Chronic myelogenous leukemia Hematology Am Soc Hematol Educ Program 2002, 111-135 12446421
10. Druker BJ Guilhot F O'Brien SG Gathmann I Kantarjian H Gattermann N Deininger MW Silver RT Goldman JM Stone RM Cervantes F Hochhaus A Powell BL Gabrilove JL Rousselot P Reiffers J Cornelissen JJ Hughes T Agis H Fischer T Verhoef G Shepherd J Saglio G Gratwohl A Nielsen JL Radich JP Simonsson B Taylor K Baccarani M So C Letvak L Larson RA IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 2006, 355:2408-2417 10.1056/ NEJMoa062867 17151364
11. Gorre ME Mohammed M Ellwood K Hsu N Paquette R Rao PN Sawyers CL Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001, 293:876-880 10.1126/ science.1062538 11423618
12. le Coutre P Tassi E Varella-Garcia M Barni R Mologni L Cabrita G Marchesi E Supino R Gambacorti-Passerini C Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 2000, 95:1758-1766 10688835
13. Pfeifer H Wassmann B Pavlova A Wunderle L Oldenburg J Binckebanck A Lange T Hochhaus A Wystub S Bruck P Hoelzer D Ottmann OG Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood 2007, Apr 3
14. Ricci C Scappini B Divoky V Gatto S Onida F Verstovsek S Kantarjian HM Beran M Mutations in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line Cancer Res 2002, 62:5995-5998 12414617
15. Hofmann WK Jones LC Lemp NA de Vos S Gschaidmeier H Hoelzer D Ottmann OG Koeffler HPNA Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation Blood 2002, 99:1860-1862 10.1182/blood.V99.5.1860 11861307
16. Roche-Lestienne C Soenen-Cornu V Grardel-Duflos N La JL Philippe N Facon T Fenaux P Preudhomme C Several types of mutations of the Abl gene be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 2002, 100:1014-1018 10.1182/blood.V100.3.1014 12130516
17. Gruber FX Hjorth-Hansen H Mikkola I Stenke L Johansen T A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib Leukemia 2006, 20:2057-2060 10.1038/ sj.leu.2404400 17008892
18. Scappini B Gatto S Onida F Ricci C Divoky V Wierda WG Andreeff M Dong L Hayes K Verstovsek S Kantarjian HM Beran M Changes associated with the development of resistance to imatinib (STI571) in two leukemic cell lines expressing p210 Bcr/Abl protein Cancer 2004, 100:1459-1471 10.1002/ cncr.20131 15042680
19. Hochhaus A Cytogenetic and molecular mechanisms of resistance to Imatinib Semin Hematol 2003, 40:69-79 12783379
20. Hochhaus A Kreil S Corbin AS La Rosee P Mueller MC Lahaye T Hanfstein B Schoch C Cross NC Berger U Gschaidmeier H Druker BJ Hehlmann R Molecular and chromosomal mechanisms of resistance to Imatinib (STI) therapy Leukemia 2002, 16:2190-2196 10.1038/sj.leu.2402741 12399961
21. Cowan-Jacob SW Guez V Fendrich G Griffin JD Fabbro D Furet P Liebetanz J Mestan J Manley PW Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment Mini Rev Med Chem 2004, 4:285-299 10.2174/ 1389557043487321 15032675
22. Ottmann OG Druker BJ Sawyers CL Goldman JM Reiffers J Silver RT Tura S Fischer T Deininger MW Schiffer CA Baccarani M Gratwohl A Hochhaus A Hoelzer D Fernandes-Reese S Gathmann I Capdeville R O'Brien SG A phase 2 study of Imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemia Blood 2002, 100:1965-1971 10.1182/blood-2001-12-0181 12200353
23. Druker BJ Sawyers CL Kantarjian H Resta DJ Reese SF Ford JM Capdeville R Talpaz M Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001, 344:1038-1042 10.1056/NEJM200104053441402 11287973
24. Weisberg E Manley PW Breitenstein W Brueggen J Cowan-Jacob SW Ray A Huntly B Fabbro D Fendrich G Hall-Meyers E Kung AL Mestan J Daley GQ Callahan L Catley L Cavazza C Azam M Mohammed A Neuberg D Wright RD Gilliland DG Griffin JD Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005, 7:129-141 10.1016/j.ccr.2005.01.007 15710326
25. Kantarjian H Giles F Wunderle L Bhalla K O'Brien S Wassmann B Tanaka C Manley P Rae P Mietlowski W Bochinski K Hochhaus A Griffin JD Hoelzer D Albitar M Dugan M Cortes J Alland L Ottmann OG Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 2006, 354:2542-2551 10.1056/NEJMoa055104 16775235
26. Verstovsek S Golemovic M Kantarjian H Manshouri T Estrov Z Manley P Sun T Arlinghaus RB Alland L Dugan M Cortes J Giles F Beran M AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells Cancer 2005, 104:1230-1236 10.1002/cncr.21299 16078266
27. Golemovic M Verstovsek S Giles F Cortes J Manshouri T Manley PW Mestan J Dugan M Alland L Griffin JD Arlinghaus RB Sun T Kantarjian H Beran M AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia Clin Cancer Res 2005, 11:4941-4947 10.1158/1078-0432.CCR-04-2601 16000593
28. O'Hare T Walters DK Stoffregen EP Jia T Manley PW Mestan J Cowan-Jacob SW Lee FY Heinrich MC Deininger MW Druker BJ In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 2005, 65:4500-4505 10.1158/0008-5472.CAN-05-0259 15930265
29. Ray A Cowan-Jacob SW Manley PW Mestan J Griffin JD Identification of Bcr/ Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (Nilotinib) by a random mutagenesis study Blood 2007 Feb 15
30. von Bubnoff N Manley PW Mestan J Sanger J Peschel C Duyster J Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) Blood 2006, 108:1328-1333 10.1182/ blood-2005-12-010132 16614241
31. Bradeen HA Eide CA O'Hare T Johnson KJ Willis SG Lee FY Druker BJ Deininger MW Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations Blood 2006, 108:2332-2338 1895563 16772610 10.1182/blood-2006-02-004580
32. Weisberg E Manley P Mestan J Cowan-Jacob S Ray A Griffin JD AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL Br J Cancer 2006, 94:1765-1769 10.1038/sj.bjc.6603170 16721371
33. Heisterkamp N Jenster G ten Hoeve J Zovich D Pattengale PK Groffen J Acute leukemia in BCR/ABL transgenic mice Nature 1990, 344:251-254 10.1038/344251a0 2179728
34. Voncken JW Griffiths S Greaves MF Pattengale PK Heisterkamp N Groffen J Restricted oncogenicity of BCR/ABL p190 in transgenic mice Cancer Res 1992, 52:4534-4539 1643646
35. Hardy RR Li YS Allman D Asano M Gui M Hayakawa K B-cell commitment, development and selection Immunol Rev 2000, 175:23-32 10.1111/ j.1600-065X.2000.imr017517.x 10933588
36. Samanta AK Lin H Sun T Kantarjian H Arlinghaus RB Janus kinase 2: A critical target in chronic myelogenous leukemia Cancer Res 2006, 66:6468-6472 10.1158/0008-5472.CAN-06-0025 16818614
37. Wang Y Cai D Brendel C Barett C Erben P Manley PW Hochhaus A Neubauer A Burchert A Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation Blood 2007, 109:2147-2155 10.1182/blood-2006-08-040022 17090651
38. Mishra S Zhang B Cunnick JM Heisterkamp N Groffen J Resistance to imatinib of bcr/abl P190 lymphoblastic leukemia cells Cancer Res 2006, 66:5387-5393 10.1158/0008-5472.CAN-05-3058 16707466
39. Mishra S Pertz V Zhang B Kaur P Shimada H Groffen J Kazimierczuk Z Pinna LA Heisterkamp N Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2 Leukemia 2007, 21:178-180 10.1038/sj.leu.2404460 17082777
40. Zhang B Groffen J Heisterkamp N Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells Leukemia 2007, 21:1189-1197 10.1038/ sj.leu.2404667 17392819
41. Xie S Wang Y Liu J Sun T Wilson MB Smithgall TE Arlinghaus RB Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation Oncogene 2001, 20:6188-6195 10.1038/sj.onc.1204834 11593427
42. Xie S Lin H Sun T Arlinghaus RB Jak2 is involved in c-Myc induction by Bcr-Abl Oncogene 2002, 21:7137-7146 10.1038/sj.onc.1205942 12370803
43. Steelman LS Pohnert SC Shelton JG Franklin RA Bertrand FE McCubrey JA AK/ STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis Leukemia 2004, 18:189-218 10.1038/sj.leu.2403241 14737178
44. Murray PJ The JAK-STAT signaling pathway: Input and output integration J Immunol 2007, 178:2623-2629 17312100
45. Rane SG Reddy EP JAKs, STATs and Src kinases in hematopoiesis Oncogene 2002, 21:3334-3358 10.1038/sj.onc.1205398 12032773
46. Ihle JN Gilliland DG Jak2: Normal function and role in hematopoietic disorders Curr Opin Genet Dev 2007, 17:8-14 10.1016/j.gde.2006.12.009 17208428
47. Zhang XF Wang JF Matczak E Proper JA Groopman JE Janus kinase 2 is involved in stromal cell-derived factor-1alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells Blood 2001, 97:3342-3348 10.1182/ blood.V97.11.3342 11369622
48. Williams RT Roussel MF Sherr CJ Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia Proc Natl Acad Sci USA 2006, 103:6688-6693 1440588 16618932 10.1073/pnas.0602030103
49. Mishra S Zhang B Groffen J Heisterkamp N A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl Leukemia 2004, 18:23-28 10.1038/ sj.leu.2403203 14603339
50. Zhang B Groffen J Heisterkamp N Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter, ATP11A Blood 2005, 106:1355-1361 1895195 15860663 10.1182/blood-2004-09-3655
51. Mishra S Reichert A Cunnick J Senadheera D Hemmeryckx B Heisterkamp N Groffen J Protein Kinase CKIIalpha interacts with the Bcr moiety of Bcr/ Abl-expressing cells Oncogene 2003, 22:8255-8262 10.1038/sj.onc.1207156 14614449
52. Sacha T Hochhaus A Hanfstein B Mueller MC Rudzki Z Czopek J Wolska-Smolen T Czekalska S Salamanchuk Z Jakobczyk M Skotnicki AB ABL-Kinase domain point mutation as a cause of Imatinib (STI 571) resistance in CML patient who progress to myeloid blast crisis Leuk Res 2003, 27:1163-1166 10.1016/S0145-2126(03)00117-6 12921956